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If essential hypertension is a disease of theories, then
renovascular hypertension is a disease of experiments.
These experiments are to a large extent the basis for our
diagnostic and therapeutic approach to the patient with
renal artery stenosis. It is not always justifiable to label
hypertension in the presence of renal artery stenosis as
renovascular hypertension. The two conditions may simply
coexist. Alternatively, it is even possible that the raised
blood pressure is the cause of the stenosis and not the other
way around-ie, hypertension increases the risk of
atherosclerotic vascular disease, which may also involve the
renal arteries.
Timely diagnosis of renovascular hypertension is
important because this condition carries a worse prognosis
than essential hypertension and seems to be less amenable
to drug treatment, with greater risks of dose-dependent
side-effects. Renovascular hypertension also carries a
higher risk of progression to accelerated or malignant
hypertension, and may result in irreversible ischaemic
failure of the affected kidney. 1,2
The prevalence of renovascular disease is less than 1 % in
the general population of hypertensives, 5% in hospital-
based populations, and up to 40% in patients referred to
hypertension clinics. In two-thirds of cases the cause of
renovascular hypertension is atherosclerotic disease; less
common causes are fibromuscular dysplasia, arteritis,
thrombosis, arterial dissection, and stenosis in a
transplanted kidney.
When to look for renal artery stenosis
Renovascular hypertension is usually symptomless.
Hypertension that is difficult to control medically is
probably the best indication that further diagnostic
evaluation is warranted. A clue is a rise in serum creatinine
during treatment with an angiotensin converting enzyme
(ACE) inhibitor. In an ongoing prospective randomised
multicentre trial of percutaneous transluminal renal
angioplasty (PTRA) vs medical treatment, we found that
the prevalence of renal artery stenosis in a group of 80
drug-resistant hypertensive patients was almost 30%.3
Drug-resistance was defined as a diastolic pressure of 95
mm Hg or above during three consecutive visits in patients
randomised to either the combination of enalapril 20 mg
and hydrochlorothiazide 25 mg or to amlodipine 10 mg with
atenolol 50 mg.
Diagnostic imaging tests are used to assess the location
and severity of the stenotic lesions. Functional diagnostic
tests are carried out to ascertain the pathophysiological
importance of the stenosis. Some functional tests can be
used to predict cure or improvement of hypertension. A




Contrast angiography is the only method for direct
visualisation of the renal arteries and is the gold standard for
comparison with less invasive procedures. Most clinicians
judge narrowing of the arterial lumen of at least 50% to be
significant, although perfusion pressure distal from the
stenosis may be maintained until the narrowing exceeds
70%.4 The frequency of serious complications requiring
medical support varies from 0-2 to 2’3%.s Intra-arterial
digital subtraction angiography with low-dose contrast
medium usually gives excellent images. However,
additional high-dose contrast arteriography may be
necessary for more detailed information. Intravenous
digital subtraction angiography is less invasive but requires
more contrast medium, and the quality of the images is
often unsatisfactory because renal branches are not
adequately displayed.l
Duplex doppler sonography and newer techniques
Duplex doppler sonography combines traditional
ultrasound imaging with a doppler technique to measure
blood flow velocities in the renal arteries. This method is
time-consuming and highly dependent on the operator.
Even when done by experienced investigators as many as
15% of studies cannot be evaluated. If one excludes such
failures, sensitivity ranges from 0 63 to 1-0 and specificity
from 0 73 to 0 96. Doppler sonography can be especially
useful for anatomical evaluation of PTRA or surgical
treatment. The first reports of magnetic resonance
imaging and three-dimensional spiral computed
tomography are promising.6 Their application outside
specialised centres needs further evaluation.
Functional diagnostic tests
Rapid sequence intravenous urography is no longer
accepted for diagnostic testing because of its low sensitivity
and specificity and the risk of nephropathy. However, it
may be helpful if one suspects coexisting urinary tract
abnormalities.
ACE inhibitor jplasma renin tests
The juxtaglomerular apparatus of the affected kidney
responds to the decreased perfusion pressure with
increased renin secretion. However, even under strictly
standardised conditions, 50% of patients with renovascular
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Figure: Evaluation of patients with renovascular disease
hypertension have peripheral vein plasma renin
concentrations within the normal ranged Curiously 10% of
patients with essential hypertension likewise have raised
plasma renin concentrations.
ACE inhibitors increase plasma renin by their
hypotensive effect and by interrupting the feedback
inhibition of renin release by angiotensin I I. The captopril-
renin test is based on the exaggerated rise in peripheral vein
renin that occurs in patients with renal artery stenosis after a
single dose of captopril of 25 or 50 mg. Depending on the
criteria for a positive test-ie, the stimulated concentration
of renin or the absolute or percentage increment in
renin-the sensitivity ranges from 0 73 to 10 in most
reports.6 The specificity of this test ranges from 0-72 to 0-95.
To achieve acceptable sensitivity, the test has to be done
under strictly standardised conditions that are often
incompatible with outpatient evaluation.
Renal scintigraphy with and without ACE inhibition
After intravenous injection of 99mTc-labelled
diethylenetriamine penta-acetic acid (DTPA) the kidney
can be visualised and the contribution of each kidney to the
total glomerular filtration rate can be estimated by external
counting.9 Glomerular filtration rate on the affected side
depends critically on angiotensin II. Consequently, ACE
inhibition leads to impairment of renal function on the
affected sides and this adverse effect of ACE inhibition can
be turned to advantage because it increases the asymmetry
between the affected and the non-affected kidney.
Scintigraphy 1 hour after 25 or 50 mg captopril is a valuable
diagnostic test." Nevertheless, improvement in detection
by the use of an ACE inhibitor is not a uniform finding.12.13
For outpatient evaluation, captopril-scintigraphy is more
accurate than the captopril-renin test.13 Captopril-
scintigraphy is also useful for detecting restenosis after
PTRA or surgery.
99mTc-labelled mercaptoacetyltriglycine (MAG3) may
replace DPTA.9 Like hippurate, and unlike DTPA, MAG3
is secreted effectively by the proximal renal tubules. MAG3
scintigraphy gives good images even when renal function is
impaired, but in patients with serum creatinine less than
200 mol/L we have found that MAG3 is no better than
DTPA for diagnosing renovascular hypertension.
Tests to predict outcome of PTRA or surgery
Renal vein renin measurements
The renal production of renin equals the product of renal
plasma flow and the veno-arterial difference in renin across
the kidney. Blood sampling from the renal artery is
unnecessary-peripheral blood can be used instead because
arterial and peripheral venous renin concentrations are the
same. The difference between the venous and arterial renin
levels (V-A) is usually small by comparison with V and A.
The standard deviation of calculated V-A difference equals
the square root of [(SDv)2+(SDA)]. This means that the
SDv_A is unacceptably high, since in renin assays the error
is proportional to the assay result. Thus the V/A ratio is
used instead of the V-A difference. An important point is
that an abnormally high V/A ratio indicates a decrease in
renal blood flow rather than an increase in renin
production.
For conclusive results, sampling conditions during
catheterisation must meet well-defined standards.14
Normally V/A averages 1 25. In about 90% of normal
kidneys the ratio is below 1 50. In 60-90% of the patients
with unilateral renal artery stenosis the ratio on the affected
side is 1-50 or more. In only 20% of normal kidneys is the
ratio 1 10 or less, whereas in 50-80% of the patients with
unilateral stenosis the ratio on the non-affected side is 1 10
or less.2,14,lS
An increased V/A renin ratio on the affected side predicts
a good outcome of PTRA or surgery, especially when the
contralateral ratio is suppressed.14 The ratio between the
venous concentrations on the affected and non-affected
sides can also be used as a prognostic index. However, with
this method it is impossible to show contralateral
suppression, and the predictive value seems to be less than
with the combined arterial and venous measurements.14
Some researchers have suggested that pretreatment with
an ACE inhibitor may increase the predictive value of renal
vein renin measurements. However, despite increased
renin production, the renal vein-to-artery renin ratio,
which is mainly related to renal blood flow, is not usually
increased." Only when renin is measured shortly after ACE
inhibition-eg, 15-45 min after captopril 25 or 50 mg-
when the arterial renin level is still rising, will the chance of
finding an increased renal V/A ratio be improved.16 A
disadvantage is the need for careful timing of captopril
dosing, especially in patients already on ACE inhibitor
treatment.
In 60-90% of patients with an increased non-stimulated
V/A renin ratio on the affected side, hypertension is cured
or improved after PTRA or surgery /4 but about half the
patients in whom the ratio is not increased likewise benefit
from these interventions. Renal vein renin measurements
therefore have limited value for predicting success of
PTRA or surgery. Stimulation with captopril does not seem
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to improve the clinical usefulness of these measurements.
Nevertheless, renal vein renin measurements may help
clinicians to decide which side contributes most to the
hypertension in patients with bilateral stenosis.17
Renal scintigraphy with ACE inhibitor
Results of a European multicentre trial indicated that an
abnormal scintigram 1 hour after captopril 25 or 50 mg is
associated with cure or improvement of hypertension after
PTRA or surgery. The sensitivity of this test was 0 95 and
the specificity 0-82.11 Much lower figures have been
reported by other groups.
Treatment
In many patients with renal artery stenosis blood pressure
can be lowered by antihypertensive drugs. Concerns
surrounding medical treatment are progression of the
stenosis and harmful effects of blood pressure reduction on
the function of the affected kidney. In a widely cited report
published in 19741s on patients with atherosclerotic renal
artery stenosis, mortality over 7 to 14 years was 73% in
patients who received drug treatment and 30 % in those who
underwent surgery (37 patients in each group). In a study
started in 1971 and reported in 1981, 4 out of 41 patients
with atherosclerotic renal artery stenosis who were
randomly selected for drug therapy progressed to complete
obstruction within 1 year. In 19 patients serum creatinine
rose by 25-120%. Thus, the results obtained with the drugs
available before 1980 were disappointing. Whether PTRA
or surgery is preferable to modern antihypertensive agents
has not been established.
The main risks of PTRA are the same as those of
arteriography.s Complications specific for PTRA are
dissection of the renal artery and cholesterol embolism.2
PTRA is the treatment of choice in patients with
fibromuscular dysplasia20 and is now also widely used in
atherosclerotic disease. A recent prospective randomised
analysis of PTRA and surgery found no significant
difference in outcome between the two approaches, which
confirms the results of earlier non-randomised studies .20,21
The less invasive character of PTRA and its lower risk,
especially in fragile elderly patients, favour PTRA over
surgery. After successful PTRA, 20% of the patients are
cured, 50% are improved, and 30% do not benefit. In
10-20% of patients PTRA is technically impossible.
In the randomised prospective study of PTRA vs
surgery,21 restenosis was observed within 2 years in 25% of
the patients after PTRA and in 4% after reconstructive
surgery. In most patients restenosis can be cured by repeat
PTRA.
There is some debate about whether ostial renal artery
stenosis is a contraindication for PTRA, because of the high
risk of restenosis. However, recent studies suggest that
PTRA can be successful in such cases.22 Sometimes a
balloon-expandable stainless steel stent may reduce the risk
of stenosis after failure of a second PTRA ;23 surgical
revascularisation is another possibility.
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